{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:02:29Z","timestamp":1794128549468,"version":"4.8.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04723-6","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:29:09Z","timestamp":1761740949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["CRISPR-mediated engineering of mesenchymal stromal\/stem cells: a summary of recent progress in immunological applications for regenerative medicine and cancer therapy"],"prefix":"10.1186","volume":"16","author":[{"given":"Mohammadreza","family":"Dashti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Mohammaddust Sarab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Shad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Dehnavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"1","key":"4723_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4723_CR2","first-page":"154","volume":"2","author":"AG Via","year":"2012","unstructured":"Via AG, Frizziero A, Oliva F. Biological properties of mesenchymal stem cells from different sources. Muscles Ligaments Tendons J. 2012;2(3):154\u201362.","journal-title":"Muscles Ligaments Tendons J"},{"issue":"12","key":"4723_CR3","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.intimp.2010.06.019","volume":"10","author":"MJ Hoogduijn","year":"2010","unstructured":"Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, et al. The Immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol. 2010;10(12):1496\u2013500.","journal-title":"Int Immunopharmacol"},{"key":"4723_CR4","doi-asserted-by":"crossref","unstructured":"Rehman A, Nigam A, Laino L, Russo D, Todisco C, Esposito G, et al. Mesenchymal stem cells in soft tissue regenerative medicine: a comprehensive review. Medicina (Kaunas Lithuania). 2023;59(8).","DOI":"10.3390\/medicina59081449"},{"issue":"1","key":"4723_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13287-025-04375-6","volume":"16","author":"M Dashti","year":"2025","unstructured":"Dashti M, Mohammadi M, Dehnavi S, Sadeghi M. Immunomodulatory interactions between mesenchymal stromal\/stem cells and immune cells in psoriasis: therapeutic potential and challenges. Stem Cell Res Ther. 2025;16(1):241.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"4723_CR6","first-page":"784","volume":"8","author":"X Fu","year":"2019","unstructured":"Fu X, Liu G, Halim A, Ju Y, Luo Q, Song GJC. Mesenchymal Stem Cell Migration Tissue Repair. 2019;8(8):784.","journal-title":"Mesenchymal Stem Cell Migration Tissue Repair"},{"key":"4723_CR7","doi-asserted-by":"crossref","unstructured":"Orbay H, Tobita M, Mizuno HJS. Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. 2012;2012(1):461718.","DOI":"10.1155\/2012\/461718"},{"key":"4723_CR8","doi-asserted-by":"crossref","unstructured":"Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci. 2022;23(17):10023.","DOI":"10.3390\/ijms231710023"},{"issue":"5","key":"4723_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s12015-023-10539-9","volume":"19","author":"G Yang","year":"2023","unstructured":"Yang G, Fan X, Liu Y, Jie P, Mazhar M, Liu Y, et al. Immunomodulatory mechanisms and therapeutic potential of mesenchymal stem cells. Stem Cell Reviews Rep. 2023;19(5):1214\u201331.","journal-title":"Stem Cell Reviews Rep"},{"key":"4723_CR10","doi-asserted-by":"crossref","unstructured":"Li J, Wu Z, Zhao L, Liu Y, Su Y, Gong X, et al. The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. 2023;14(1):381.","DOI":"10.1186\/s13287-023-03587-y"},{"issue":"1","key":"4723_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13287-022-02782-7","volume":"13","author":"SA Jasim","year":"2022","unstructured":"Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A, Suksatan W, et al. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther. 2022;13(1):101.","journal-title":"Stem Cell Res Ther"},{"key":"4723_CR12","doi-asserted-by":"publisher","first-page":"110367","DOI":"10.1016\/j.intimp.2023.110367","volume":"120","author":"M Gholami","year":"2023","unstructured":"Gholami M, Ghorban K, Sadeghi M, Dadmanesh M, Rouzbahani NH, Dehnavi S. Mesenchymal stem cells and allergic airway inflammation; a therapeutic approach to induce immunoregulatory responses. Int Immunopharmacol. 2023;120:110367.","journal-title":"Int Immunopharmacol"},{"key":"4723_CR13","doi-asserted-by":"crossref","unstructured":"Li Y, Jin M, Guo D, Shen S, Lu K, Pan R, et al. Unveiling the immunogenicity of allogeneic mesenchymal stromal cells: challenges and strategies for enhanced therapeutic efficacy. Biomed Pharmacother; 2024;180:117537.","DOI":"10.1016\/j.biopha.2024.117537"},{"issue":"6","key":"4723_CR14","doi-asserted-by":"publisher","first-page":"e13267","DOI":"10.1111\/sji.13267","volume":"97","author":"W Chen","year":"2023","unstructured":"Chen W, Lv L, Chen N, Cui E. Immunogenicity of mesenchymal stromal\/stem cells. Scand J Immunol. 2023;97(6):e13267.","journal-title":"Scand J Immunol"},{"key":"4723_CR15","first-page":"957153","volume":"9","author":"A Cequier","year":"2022","unstructured":"Cequier A, V\u00e1zquez FJ, Romero A, Vitoria A, Bernad E, Garcia-Martinez M, et al. The immunomodulation\u2013immunogenicity balance of equine mesenchymal stem cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histoCompatibility complex (MHC). Compatibility. 2022;9:957153.","journal-title":"Compatibility"},{"issue":"2","key":"4723_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00018-020-03600-0","volume":"78","author":"LA Costa","year":"2021","unstructured":"Costa LA, Eiro N, Fraile M, Gonzalez LO, Sa\u00e1 J, Garcia-Portabella P, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cell Mol Life Sci. 2021;78(2):447\u201367.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"4723_CR17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","volume":"187","author":"M Pacesa","year":"2024","unstructured":"Pacesa M, Pelea O, Jinek M. Past, present, and future of CRISPR genome editing technologies. Cell. 2024;187(5):1076\u2013100.","journal-title":"Cell"},{"issue":"12","key":"4723_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.tplants.2019.09.006","volume":"24","author":"H Manghwar","year":"2019","unstructured":"Manghwar H, Lindsey K, Zhang X, Jin S. CRISPR\/Cas system: recent advances and future prospects for genome editing. Trends Plant Sci. 2019;24(12):1102\u201325.","journal-title":"Trends Plant Sci"},{"key":"4723_CR19","doi-asserted-by":"crossref","unstructured":"Liu W, Li L, Jiang J, Wu M, Lin PJP. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. 2021;4(3):179\u201391.","DOI":"10.1093\/pcmedi\/pbab014"},{"issue":"6","key":"4723_CR20","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"D Hsu Patrick","year":"2014","unstructured":"Hsu Patrick D, Lander Eric S, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262\u201378.","journal-title":"Cell"},{"issue":"7","key":"4723_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF. III. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397\u2013405.","journal-title":"Trends Biotechnol"},{"key":"4723_CR22","first-page":"353","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-Mediated genome editing. Biologics: Targets Therapy. 2021;15:353\u201361.","journal-title":"Biologics: Targets Therapy"},{"issue":"22","key":"4723_CR23","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1128\/MCB.00512-15","volume":"35","author":"MF La Russa","year":"2015","unstructured":"La Russa MF, Qi LS. The new state of the art: Cas9 for gene activation and repression. Mol Cell Biol. 2015;35(22):3800\u20139.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"4723_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1021\/acssynbio.5b00299","volume":"6","author":"RM Daer","year":"2017","unstructured":"Daer RM, Cutts JP, Brafman DA, Haynes KA. The impact of chromatin dynamics on Cas9-Mediated genome editing in human cells. ACS Synth Biol. 2017;6(3):428\u201338.","journal-title":"ACS Synth Biol"},{"key":"4723_CR25","doi-asserted-by":"publisher","first-page":"118525","DOI":"10.1016\/j.lfs.2020.118525","volume":"263","author":"A Hazafa","year":"2020","unstructured":"Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, et al. CRISPR\/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020;263:118525.","journal-title":"Life Sci"},{"key":"4723_CR26","doi-asserted-by":"publisher","first-page":"104771","DOI":"10.1016\/j.cellimm.2023.104771","volume":"393\u2013394","author":"S Dehnavi","year":"2023","unstructured":"Dehnavi S, Sadeghi M, Tavakol Afshari J, Mohammadi M. Interactions of mesenchymal stromal\/stem cells and immune cells following MSC-based therapeutic approaches in rheumatoid arthritis. Cell Immunol. 2023;393\u2013394:104771.","journal-title":"Cell Immunol"},{"key":"4723_CR27","doi-asserted-by":"crossref","unstructured":"Cai R, Lv R, Shi X, Yang G, Jin J. CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation. Int J Mol Sci. 2023;24(19).","DOI":"10.3390\/ijms241914865"},{"issue":"1","key":"4723_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","volume":"43","author":"B Paul","year":"2020","unstructured":"Paul B, Montoya G. CRISPR-Cas12a: functional overview and applications. Biomedical J. 2020;43(1):8\u201317.","journal-title":"Biomedical J"},{"issue":"7675","key":"4723_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"OO Abudayyeh","year":"2017","unstructured":"Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR\u2013Cas13. Nature. 2017;550(7675):280\u20134.","journal-title":"Nature"},{"issue":"1","key":"4723_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cell.2019.05.049","volume":"178","author":"S Rauch","year":"2019","unstructured":"Rauch S, He E, Srienc M, Zhou H, Zhang Z, Dickinson BC. Programmable RNA-Guided RNA effector proteins built from human parts. Cell. 2019;178(1):122\u2013e3412.","journal-title":"Cell"},{"issue":"6096","key":"4723_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Sci (New York NY). 2012;337(6096):816\u201321.","journal-title":"Sci (New York NY)"},{"issue":"7","key":"4723_CR32","first-page":"838","volume":"39","author":"J Chen","year":"2021","unstructured":"Chen J, Zheng C-X, Jin Y, Hu C-H. Mesenchymal stromal cell-mediated immune regulation: A promising remedy in the therapy of type 2 diabetes mellitus. Stem cells (Dayton. Ohio). 2021;39(7):838\u201352.","journal-title":"Ohio)"},{"issue":"5","key":"4723_CR33","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","volume":"152","author":"LS Qi","year":"2013","unstructured":"Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173\u201383.","journal-title":"Cell"},{"key":"4723_CR34","doi-asserted-by":"crossref","unstructured":"Meng X, Zheng M, Liu J, Bai W, Zuo L, Bu X, et al. Transplantation of CRISPRa system engineered IL10-overexpressing bone marrow-derived mesenchymal stem cells for the treatment of myocardial infarction in diabetic mice. J Biol Eng. 2019;13.","DOI":"10.1186\/s13036-019-0163-6"},{"issue":"1","key":"4723_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12195-025-00843-4","volume":"18","author":"I Martinez-Zalbidea","year":"2025","unstructured":"Martinez-Zalbidea I, Wagner G, Bergendahl N, Mesfin A, Puvanesarajah V, Hitzl W, et al. CRISPR-dCas9 activation of TSG-6 in MSCs modulates the cargo of MSC-Derived extracellular vesicles and attenuates inflammatory responses in human intervertebral disc cells in vitro. Cell Mol Bioeng. 2025;18(1):83\u201398.","journal-title":"Cell Mol Bioeng"},{"issue":"3","key":"4723_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759\u201371.","journal-title":"Cell"},{"issue":"1","key":"4723_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nbt.3737","volume":"35","author":"B Zetsche","year":"2017","unstructured":"Zetsche B, Heidenreich M, Mohanraju P, Fedorova I, Kneppers J, DeGennaro EM, et al. Multiplex gene editing by CRISPR-Cpf1 using a single CrRNA array. Nat Biotechnol. 2017;35(1):31\u20134.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4723_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41556-019-0454-7","volume":"22","author":"AA Smargon","year":"2020","unstructured":"Smargon AA, Shi YJ, Yeo GW. RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering. Nat Cell Biol. 2020;22(2):143\u201350.","journal-title":"Nat Cell Biol"},{"key":"4723_CR39","doi-asserted-by":"publisher","first-page":"113943","DOI":"10.1016\/j.biopha.2022.113943","volume":"156","author":"A Hazrati","year":"2022","unstructured":"Hazrati A, Malekpour K, Soudi S, Hashemi SM. CRISPR\/Cas9-engineered mesenchymal stromal\/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations. Biomed Pharmacother. 2022;156:113943.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4723_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5483\/BMBRep.2023-0113","volume":"57","author":"AR Han","year":"2024","unstructured":"Han AR, Shin HR, Kwon J, Lee SB, Lee SE, Kim EY, et al. Highly efficient genome editing via CRISPR-Cas9 ribonucleoprotein (RNP) delivery in mesenchymal stem cells. BMB Rep. 2024;57(1):60\u20135.","journal-title":"BMB Rep"},{"key":"4723_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/5584_2019_459","volume":"1247","author":"A Golchin","year":"2020","unstructured":"Golchin A, Shams F, Karami F. Advancing mesenchymal stem cell therapy with CRISPR\/Cas9 for clinical trial studies. Adv Exp Med Biol. 2020;1247:89\u2013100.","journal-title":"Adv Exp Med Biol"},{"key":"4723_CR42","doi-asserted-by":"crossref","unstructured":"Crippa S, Conti A, Vavassori V, Ferrari S, Beretta S, Rivis S, et al. Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs. 2023;31(1):230\u201348.","DOI":"10.1016\/j.ymthe.2022.08.011"},{"issue":"1","key":"4723_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13578-021-00698-y","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Zhao H, Cheng L, Wang B. Allogeneic vs. autologous mesenchymal stem\/stromal cells in their medication practice. Cell Bioscience. 2021;11(1):187.","journal-title":"Cell Bioscience"},{"issue":"6","key":"4723_CR44","first-page":"e13267","volume":"97","author":"W Chen","year":"2023","unstructured":"Chen W, Lv L, Chen N, Cui EJSJI. Immunogenicity Mesenchymal stromal\/stem Cells. 2023;97(6):e13267.","journal-title":"Immunogenicity Mesenchymal stromal\/stem Cells"},{"issue":"3","key":"4723_CR45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252\u201360.","journal-title":"Nat Biotechnol"},{"key":"4723_CR46","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3389\/fimmu.2017.01626","volume":"8","author":"P Lohan","year":"2017","unstructured":"Lohan P, Treacy O, Griffin MD, Ritter T, Ryan AE. Anti-Donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning? Front Immunol. 2017;8:1626.","journal-title":"Front Immunol"},{"key":"4723_CR47","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Y, Shao L, Pan X, Liang C, Liu B, et al. Knockout of beta-2 microglobulin reduces stem cell\u2010induced immune rejection and enhances ischaemic hindlimb repair via exosome\/miR\u201024\/Bim pathway. 2020;24(1):695\u2013710.","DOI":"10.1111\/jcmm.14778"},{"key":"4723_CR48","first-page":"096368972096552","volume":"29","author":"S Zha","year":"2020","unstructured":"Zha S, Tay JC-K, Zhu S, Li Z, Du Z, Wang S. Generation of mesenchymal stromal cells with low immunogenicity from human PBMC-Derived \u03b22. Microglobulin Knockout Induc Pluripotent Stem Cells. 2020;29:0963689720965529.","journal-title":"Microglobulin Knockout Induc Pluripotent Stem Cells"},{"issue":"5","key":"4723_CR49","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00018-019-03220-3","volume":"77","author":"L Shao","year":"2020","unstructured":"Shao L, Zhang Y, Pan X, Liu B, Liang C, Zhang Y, et al. Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection. Cell Mol Life Sci. 2020;77(5):937\u201352.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4723_CR50","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12015-020-09990-9","volume":"16","author":"D Kwon","year":"2020","unstructured":"Kwon D, Ahn HJ, Han MJ, Ji M, Ahn J, Seo KW, et al. Human leukocyte antigen class I Pseudo-Homozygous mesenchymal stem cells derived from human induced pluripotent stem cells. Stem Cell Rev Rep. 2020;16(4):792\u2013808.","journal-title":"Stem Cell Rev Rep"},{"key":"4723_CR51","doi-asserted-by":"publisher","first-page":"102580","DOI":"10.1016\/j.scr.2021.102580","volume":"57","author":"E Romano","year":"2021","unstructured":"Romano E, Trionfini P, Giampietro R, Benigni A, Tomasoni S. Generation of a homozygous CIITA knockout iPS cell line using the CRISPR-Cas9 system. Stem Cell Res. 2021;57:102580.","journal-title":"Stem Cell Res"},{"key":"4723_CR52","doi-asserted-by":"publisher","first-page":"1403395","DOI":"10.3389\/fgeed.2024.1403395","volume":"6","author":"HR Frederiksen","year":"2024","unstructured":"Frederiksen HR, Glantz A, V\u00f8ls KK, Skov S, Tveden-Nyborg P, Freude K, et al. CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice. Front Genome Editing. 2024;6:1403395.","journal-title":"Front Genome Editing"},{"issue":"1","key":"4723_CR53","doi-asserted-by":"publisher","first-page":"e12712","DOI":"10.1111\/cpr.12712","volume":"53","author":"W Jiang","year":"2020","unstructured":"Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712.","journal-title":"Cell Prolif"},{"issue":"2","key":"4723_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cellimm.2011.05.010","volume":"270","author":"G Raicevic","year":"2011","unstructured":"Raicevic G, Najar M, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, et al. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol. 2011;270(2):207\u201316.","journal-title":"Cell Immunol"},{"issue":"6","key":"4723_CR55","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.apsb.2022.12.013","volume":"13","author":"C Chen","year":"2023","unstructured":"Chen C, Zhong W, Du S, Li Y, Zeng Y, Liu K, et al. Intelligent nanotherapeutic strategies for the delivery of CRISPR system. Acta Pharm Sinica B. 2023;13(6):2510\u201343.","journal-title":"Acta Pharm Sinica B"},{"issue":"43","key":"4723_CR56","doi-asserted-by":"publisher","first-page":"48259","DOI":"10.1021\/acsami.0c10885","volume":"12","author":"YL Luo","year":"2020","unstructured":"Luo YL, Liang LF, Gan YJ, Liu J, Zhang Y, Fan YN, et al. An All-in-One nanomedicine consisting of CRISPR-Cas9 and an autoantigen peptide for restoring specific immune tolerance. ACS Appl Mater Interfaces. 2020;12(43):48259\u201371.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4723_CR57","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Delivery. 2018;25(1):1234\u201357.","journal-title":"Drug Delivery"},{"issue":"2","key":"4723_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/thno.47007","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Shen J, Li D, Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. Theranostics. 2021;11(2):614\u201348.","journal-title":"Theranostics"},{"issue":"1","key":"4723_CR59","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1038\/s41598-018-30227-w","volume":"8","author":"X Xu","year":"2018","unstructured":"Xu X, Gao D, Wang P, Chen J, Ruan J, Xu J, et al. Efficient homology-directed gene editing by CRISPR\/Cas9 in human stem and primary cells using tube electroporation. Sci Rep. 2018;8(1):11649.","journal-title":"Sci Rep"},{"issue":"7","key":"4723_CR60","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.apsb.2025.04.022","volume":"15","author":"Y Hui","year":"2025","unstructured":"Hui Y, Jiao X, Yang L, Lu D, Han Y, Yang W, et al. Indoleamine-2,3-dioxygenase: an important controller in maintaining mesenchymal stem cell-mediated Immunomodulatory homeostasis. Acta Pharm Sinica B. 2025;15(7):3404\u201318.","journal-title":"Acta Pharm Sinica B"},{"key":"4723_CR61","doi-asserted-by":"crossref","unstructured":"Yudhawati R, Shimizu K. PGE2 produced by exogenous MSCs promotes immunoregulation in ARDS induced by highly pathogenic influenza A through activation of the Wnt-\u03b2-Catenin signaling pathway. Int J Mol Sci. 2023;24(8).","DOI":"10.3390\/ijms24087299"},{"key":"4723_CR62","doi-asserted-by":"crossref","unstructured":"Hazrati A, Malekpour K, Soudi S, Hashemi SM. CRISPR\/Cas9-engineered mesenchymal stromal\/stem cells and their extracellular vesicles: a new approach to overcoming cell therapy limitations. Biomed Pharmacother. 2022;156:113943.","DOI":"10.1016\/j.biopha.2022.113943"},{"key":"4723_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13036-019-0163-6","volume":"13","author":"X Meng","year":"2019","unstructured":"Meng X, Zheng M, Yu M, Bai W, Zuo L, Bu X, et al. Transplantation of CRISPRa system engineered IL10-overexpressing bone marrow-derived mesenchymal stem cells for the treatment of myocardial infarction in diabetic mice. J Biol Eng. 2019;13:49.","journal-title":"J Biol Eng"},{"issue":"1","key":"4723_CR64","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5483\/BMBRep.2021.54.1.245","volume":"54","author":"S Kim","year":"2021","unstructured":"Kim S, Hupperetz C, Lim S, Kim CH. Genome editing of immune cells using CRISPR\/Cas9. BMB Rep. 2021;54(1):59\u201369.","journal-title":"BMB Rep"},{"key":"4723_CR65","doi-asserted-by":"crossref","unstructured":"Hu Y, Liu S, Zhu B-M. CRISPR\/Cas9-induced loss of Keap1 enhances anti-oxidation in rat adipose-derived mesenchymal stem cells. 2020;10:2019.","DOI":"10.3389\/fneur.2019.01311"},{"issue":"9","key":"4723_CR66","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.freeradbiomed.2009.07.035","volume":"47","author":"JW Kaspar","year":"2009","unstructured":"Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47(9):1304\u20139.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"4723_CR67","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1038\/s41598-023-31286-4","volume":"13","author":"Y Schary","year":"2023","unstructured":"Schary Y, Rotem I, Caller T, Lewis N, Shaihov-Teper O, Brzezinski RY, et al. CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy. Sci Rep. 2023;13(1):4481.","journal-title":"Sci Rep"},{"key":"4723_CR68","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3389\/fimmu.2019.01659","volume":"10","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Choi B, Kim Y, Lee SE, Jin HJ, Lee HS, et al. The upregulation of Toll-Like receptor 3 via autocrine IFN-\u03b2 signaling drives the senescence of human umbilical cord Blood-Derived mesenchymal stem cells through JAK1. Front Immunol. 2019;10:1659.","journal-title":"Front Immunol"},{"issue":"1","key":"4723_CR69","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1038\/s41467-018-06898-4","volume":"9","author":"Y Wu","year":"2018","unstructured":"Wu Y, Xie L, Wang M, Xiong Q, Guo Y, Liang Y, et al. Mettl3-mediated m(6)A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun. 2018;9(1):4772.","journal-title":"Nat Commun"},{"issue":"3","key":"4723_CR70","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4093\/dmj.2023.0174","volume":"48","author":"H Kang","year":"2024","unstructured":"Kang H, Park Y-K, Lee J-Y, Bae M. Roles of histone deacetylase 4 in the inflammatory and metabolic processes. Diabetes Metab J. 2024;48(3):340\u201353.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"4723_CR71","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s13018-024-05163-3","volume":"19","author":"S-H Park","year":"2024","unstructured":"Park S-H, Kim J, Yang H-J, Lee JY, Kim CH, Hur JK, et al. CRISPR activation identifies a novel miR-2861 binding site that facilitates the osteogenesis of human mesenchymal stem cells. J Orthop Surg Res. 2024;19(1):730.","journal-title":"J Orthop Surg Res"},{"key":"4723_CR72","doi-asserted-by":"crossref","unstructured":"Hirakawa MP, Tjahjono N, Light YK, Chintalapudi P, Butler KS, Branda SS, et al. Augmentation of antibacterial activity in mesenchymal stromal cells through systems-level analysis and CRISPR-mediated activation of CD14. bioRxiv. 2020:2020.10.14.338020.","DOI":"10.1101\/2020.10.14.338020"},{"key":"4723_CR73","doi-asserted-by":"publisher","first-page":"112624","DOI":"10.1016\/j.msec.2021.112624","volume":"133","author":"B Wang","year":"2022","unstructured":"Wang B, Chang M, Zhang R, Wo J, Wu B, Zhang H, et al. Spinal cord injury target-immunotherapy with TNF-\u03b1 autoregulated and feedback-controlled human umbilical cord mesenchymal stem cell derived exosomes remodelled by CRISPR\/Cas9 plasmid. Biomaterials Adv. 2022;133:112624.","journal-title":"Biomaterials Adv"},{"issue":"1","key":"4723_CR74","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1038\/s41467-020-16065-3","volume":"11","author":"W Srifa","year":"2020","unstructured":"Srifa W, Kosaric N, Amorin A, Jadi O, Park Y, Mantri S, et al. Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice. Nat Commun. 2020;11(1):2470.","journal-title":"Nat Commun"},{"key":"4723_CR75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.18632\/oncotarget.28672","volume":"15","author":"T Minev","year":"2024","unstructured":"Minev T, Balbuena S, Gill JM, Marincola FM, Kesari S, Lin F. Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists. Oncotarget. 2024;15:793\u2013805.","journal-title":"Oncotarget"},{"key":"4723_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2020.07.015","volume":"158","author":"D Huang","year":"2020","unstructured":"Huang D, Miller M, Ashok B, Jain S, Peppas NA. CRISPR\/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. Adv Drug Deliv Rev. 2020;158:17\u201335.","journal-title":"Adv Drug Deliv Rev"},{"key":"4723_CR77","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1182\/blood-2018-99-116921","volume":"132","author":"N Dunavin","year":"2018","unstructured":"Dunavin N, Li M, Atay S, Mitchell J, Soder R, Abhyankar S, et al. CRISPR\/Cas9-Mediated disruption of PD-L1 reduces the T cell suppressive effect of wharton\u2019s jelly mesenchymal stromal cells and their extracellular vesicles. Blood. 2018;132:5095.","journal-title":"Blood"},{"issue":"1","key":"4723_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.","journal-title":"Mol Cancer"},{"issue":"1","key":"4723_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cjtee.2023.11.003","volume":"27","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yao MW, Ao X, Gong QJ, Yang Y, Liu JX, et al. The expression mechanism of programmed cell death 1 ligand 1 and its role in Immunomodulatory ability of mesenchymal stem cells. Chin J Traumatol = Zhonghua Chuang Shang Za Zhi. 2024;27(1):1\u201310.","journal-title":"Chin J Traumatol = Zhonghua Chuang Shang Za Zhi"},{"issue":"2","key":"4723_CR80","first-page":"296","volume":"1866","author":"S Keshavarz","year":"2019","unstructured":"Keshavarz S, Nassiri SM, Siavashi V, Alimi NS. Regulation of plasticity and biological features of endothelial progenitor cells by MSC-derived SDF-1. Biochimica et biophysica acta (BBA) -. Mol Cell Res. 2019;1866(2):296\u2013304.","journal-title":"Mol Cell Res"},{"key":"4723_CR81","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1084\/jem.20080730","volume":"205","author":"M Meiron","year":"2008","unstructured":"Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med. 2008;205:2643\u201355.","journal-title":"J Exp Med"},{"key":"4723_CR82","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","volume":"177","author":"W Zhang","year":"2024","unstructured":"Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials. Biomed Pharmacother. 2024;177:116930.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4723_CR83","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s11658-021-00273-w","volume":"26","author":"S Babazadeh","year":"2021","unstructured":"Babazadeh S, Nassiri SM, Siavashi V, Sahlabadi M, Hajinasrollah M, Zamani-Ahmadmahmudi M. Macrophage polarization by MSC-derived CXCL12 determines tumor growth. Cell Mol Biol Lett. 2021;26(1):30.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"4723_CR84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2009.11.009","volume":"21","author":"J Zhang","year":"2010","unstructured":"Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21(1):41\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"4723_CR85","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1593\/neo.09988","volume":"11","author":"K Mizutani","year":"2009","unstructured":"Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia (New York NY). 2009;11(11):1235\u201342.","journal-title":"Neoplasia (New York NY)"},{"key":"4723_CR86","doi-asserted-by":"crossref","unstructured":"Bui QT, Lee KD, Fan YC, Lewis BS, Deng LW, Tsai YC. Disruption of CCL2 in mesenchymal stem cells as an anti-tumor approach against prostate cancer. Cancers. 2023;15(2).","DOI":"10.3390\/cancers15020441"},{"key":"4723_CR87","doi-asserted-by":"crossref","unstructured":"Tang S, Zhang Y, Wang P, Tang Q, Liu Y, Lu F, et al. NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand. iScience. 2025;28(5).","DOI":"10.1016\/j.isci.2025.112343"},{"issue":"12","key":"4723_CR88","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.4049\/jimmunol.137.12.3909","volume":"137","author":"SM Goyert","year":"1986","unstructured":"Goyert SM, Ferrero EM, Seremetis SV, Winchester RJ, Silver J, Mattison AC. Biochemistry and expression of myelomonocytic antigens. J Immunol. 1986;137(12):3909\u201314.","journal-title":"J Immunol"},{"issue":"6","key":"4723_CR89","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/1074-7613(94)90093-0","volume":"1","author":"J Pugin","year":"1994","unstructured":"Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, et al. CD14 is a pattern recognition receptor. Immunity. 1994;1(6):509\u201316.","journal-title":"Immunity"},{"key":"4723_CR90","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev.iy.13.040195.002253","volume":"13","author":"RJ Ulevitch","year":"1995","unstructured":"Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437\u201357.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"4723_CR91","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jcyt.2020.03.480","volume":"22","author":"K Lee","year":"2020","unstructured":"Lee K, Lee N, Shin E, Lee N, Chang J, Na D, et al. Enhancing the therapeutic potential of mesenchymal stem cell-based therapy via CRISPR\/Cas9-based genome editing. Cytotherapy. 2020;22(5):S15.","journal-title":"Cytotherapy"},{"key":"4723_CR92","doi-asserted-by":"crossref","unstructured":"Wechsler ME, Rao VV, Borelli AN, Anseth KSJAhm. Engineering the MSC secretome: a hydrogel focused approach. 2021;10(7):2001948.","DOI":"10.1002\/adhm.202001948"},{"key":"4723_CR93","doi-asserted-by":"publisher","first-page":"725398","DOI":"10.3389\/fnins.2021.725398","volume":"15","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Bayarsaikhan D, Lee J, Bayarsaikhan G, Lee B. Brain-Derived neurotrophic factor secreting human mesenchymal stem cells improve outcomes in Rett syndrome mouse models. Front NeuroSci. 2021;15:725398.","journal-title":"Front NeuroSci"},{"issue":"3","key":"4723_CR94","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","volume":"4","author":"W Liu","year":"2021","unstructured":"Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clin Med. 2021;4(3):179\u201391.","journal-title":"Precision Clin Med"},{"key":"4723_CR95","doi-asserted-by":"crossref","unstructured":"Yang Y, Xu J, Ge S, Lai L. CRISPR\/Cas: advances, limitations, and applications for precision cancer research. 2021;8:2021.","DOI":"10.3389\/fmed.2021.649896"},{"key":"4723_CR96","doi-asserted-by":"crossref","unstructured":"Zhang S, Shen J, Li D, Cheng YJT. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. 2021;11(2):614.","DOI":"10.7150\/thno.47007"},{"issue":"1","key":"4723_CR97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"S-W Wang","year":"2022","unstructured":"Wang S-W, Gao C, Zheng Y-M, Yi L, Lu J-C, Huang X-Y, et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57.","journal-title":"Mol Cancer"},{"key":"4723_CR98","unstructured":"Golchin A, Shams F, Karami F. Advancing mesenchymal stem cell therapy with CRISPR\/Cas9 for clinical trial studies. 12472019."},{"key":"4723_CR99","doi-asserted-by":"crossref","unstructured":"Filho DM, de Carvalho Ribeiro P, Oliveira LF, Dos Santos ALRT, Parreira RC, Pinto MCX et al. Enhancing the therapeutic potential of mesenchymal stem cells with the CRISPR-Cas system. 2019;15(4):463\u201373.","DOI":"10.1007\/s12015-019-09897-0"},{"issue":"3","key":"4723_CR100","doi-asserted-by":"publisher","first-page":"e0238330","DOI":"10.1371\/journal.pone.0238330","volume":"16","author":"T Gross","year":"2021","unstructured":"Gross T, Jeney C, Halm D, Finkenzeller G, Stark GB, Zengerle R, et al. Characterization of CRISPR\/Cas9 RANKL knockout mesenchymal stem cell clones based on single-cell printing technology and emulsion coupling assay as a low-cellularity workflow for single-cell cloning. PLoS ONE. 2021;16(3):e0238330.","journal-title":"PLoS ONE"},{"issue":"1","key":"4723_CR101","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13287-025-04158-z","volume":"16","author":"A Hoseinzadeh","year":"2025","unstructured":"Hoseinzadeh A, Esmaeili S-A, Sahebi R, Melak AM, Mahmoudi M, Hasannia M, et al. Fate and long-lasting therapeutic effects of mesenchymal stromal\/stem-like cells: mechanistic insights. Stem Cell Res Ther. 2025;16(1):33.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"4723_CR102","doi-asserted-by":"publisher","first-page":"200","DOI":"10.23876\/j.krcp.2017.36.2.200","volume":"36","author":"JS Kim","year":"2017","unstructured":"Kim JS, Lee JH, Kwon O, Cho JH, Choi JY, Park SH, et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney Res Clin Pract. 2017;36(2):200\u20134.","journal-title":"Kidney Res Clin Pract"},{"issue":"5","key":"4723_CR103","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jcyt.2020.03.139","volume":"22","author":"JC Fitzgerald","year":"2020","unstructured":"Fitzgerald JC, Hanley S, Barry F. Phenotypic instability of mesenchymal stromal cells isolated and expanded in different growth media. Cytotherapy. 2020;22(5):S84.","journal-title":"Cytotherapy"},{"issue":"49","key":"4723_CR104","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1038\/s41388-024-03183-1","volume":"43","author":"R Antoon","year":"2024","unstructured":"Antoon R, Overdevest N, Saleh AH, Keating A. Mesenchymal stromal cells as cancer promoters. Oncogene. 2024;43(49):3545\u201355.","journal-title":"Oncogene"},{"issue":"9","key":"4723_CR105","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822\u20136.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4723_CR106","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/mt.2015.100","volume":"23","author":"S Yagyu","year":"2015","unstructured":"Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. An inducible Caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells. Mol Ther. 2015;23(9):1475\u201385.","journal-title":"Mol Ther"},{"issue":"2","key":"4723_CR107","first-page":"146","volume":"9","author":"A Kenarkoohi","year":"2020","unstructured":"Kenarkoohi A, Bamdad T, Soleimani M, Soleimanjahi H, Fallah A, Falahi S. HSV-TK expressing mesenchymal stem cells exert inhibitory effect on cervical cancer model. Int J Mol Cell Med. 2020;9(2):146\u201354.","journal-title":"Int J Mol Cell Med"},{"issue":"6","key":"4723_CR108","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/stem.433","volume":"28","author":"CA Ramos","year":"2010","unstructured":"Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, et al. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010;28(6):1107\u201315.","journal-title":"Stem Cells"},{"issue":"1","key":"4723_CR109","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41417-018-0034-1","volume":"26","author":"F Rossignoli","year":"2019","unstructured":"Rossignoli F, Grisendi G, Spano C, Golinelli G, Recchia A, Rovesti G, et al. Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. Cancer Gene Ther. 2019;26(1):11\u20136.","journal-title":"Cancer Gene Ther"},{"key":"4723_CR110","doi-asserted-by":"crossref","unstructured":"Falcon C, Smith L, Al-Obaidi M, Abu Zaanona M, Purvis K, Minagawa K ,et al. Combinatorial suicide gene strategies for the safety of cell therapies. 2022;13:2022.","DOI":"10.3389\/fimmu.2022.975233"},{"key":"4723_CR111","unstructured":"Hospital SJCsR. Gene editing for sickle cell disease. 2025."},{"issue":"2","key":"4723_CR112","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s12015-024-10812-5","volume":"21","author":"M Strecanska","year":"2025","unstructured":"Strecanska M, Sekelova T, Smolinska V, Kuniakova M, Nicodemou A. Automated manufacturing processes and platforms for Large-scale production of Clinical-grade mesenchymal Stem\/ stromal cells. Stem Cell Rev Rep. 2025;21(2):372\u201389.","journal-title":"Stem Cell Rev Rep"},{"key":"4723_CR113","doi-asserted-by":"crossref","unstructured":"Calascibetta F, Martorana A, Lo Pinto M, Carcione C, D\u2019Arpa S, Amico G, et al. GMP-compliant, serum-free cultures preserve therapeutic potential of extracellular vesicles from human mesenchymal stromal cells. 2025;13:2025.","DOI":"10.3389\/fcell.2025.1633912"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04723-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:05:13Z","timestamp":1761743113000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04723-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4723"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04723-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"592"}}